BLCO

Bausch + Lomb stock walked into this Q3 2026 report quietly, flat at US$20.40 and up only modestly over the past quarter. The share price barely flinched after the release. The earnings story did not.

Key TakeawaysBausch Health jumped 21% after adjusted EPS of $1. 77 beat estimates, and it raised its outlook again.

Bausch + Lomb (NYSE:BLCO) reported third-quarter revenue growth across all three business segments, raised its full-year outlook for the third time in 2026 and highlighted continued margin expansion and cash generation as interim Chief Executive Officer Tom…

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) jumped 8.7% in the afternoon session after the company reported third-quarter 2026 revenue of $1.375 billion and raised its full-year 2026 revenue guidance.

Bausch Health Cos (NYSE:BHC) raised its full-year 2026 outlook for the second consecutive quarter after reporting third-quarter growth across its operating segments, led by Salix and supported by international operations and Solta Medical.

Investing.com -- Bausch Health Companies Inc. (NYSE: BHC) reported third quarter results that exceeded analyst expectations, with adjusted earnings per share of $1.77, beating the consensus estimate of $1.27 by $0.50.

Key TakeawaysBausch + Lomb shares jumped 16% after a third-quarter profit beat and raised full-year guidance. Profit is the story: adjusted EBITDA rose 34% on 7% revenue growth.

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third quarter 2026 financial results and other key updates from the quarter.

VAUGHAN, Ontario (AP) — VAUGHAN, Ontario (AP) — Bausch + Lomb Corporation (BLCO) on Wednesday reported third-quarter net income of $32 million, after reporting a loss in the same period a year earlier.The Vaughan, Ontario-based company said it had net income…

Moby summary of Bausch + Lomb Corporation's Q3 2026 earnings call